BR0009016A - Composição de apomorfina e sildenafil - Google Patents

Composição de apomorfina e sildenafil

Info

Publication number
BR0009016A
BR0009016A BR0009016-6A BR0009016A BR0009016A BR 0009016 A BR0009016 A BR 0009016A BR 0009016 A BR0009016 A BR 0009016A BR 0009016 A BR0009016 A BR 0009016A
Authority
BR
Brazil
Prior art keywords
sildenafil
apomorphine
administered
composition
treatment
Prior art date
Application number
BR0009016-6A
Other languages
English (en)
Inventor
Ragab El-Rashidy
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of BR0009016A publication Critical patent/BR0009016A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO DE APOMORFINA E SILDENAFIL". Tratamento de disfunção sexual em pacientes humanos através de um regime de terapia oral de administração de apomorfina e sildenafil é disposto. Esse tratamento otimiza a eficácia de cada droga e substancialmente minimiza os efeitos colaterais indesejáveis associados a eles individualmente. A apomorfina e o sildenafil podem ser co-administrados com uma unidade de dosagem de combinação ou administrada seq³encialmente em unidades de dosagem separadas, substancialmente antes da atividade sexual. Outro agente eretogênico pode ser administrado com apomorfina e sildenafil.
BR0009016-6A 1999-03-16 2000-03-14 Composição de apomorfina e sildenafil BR0009016A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/270,035 US6087362A (en) 1999-03-16 1999-03-16 Apomorphine and sildenafil composition
PCT/US2000/006654 WO2000054774A1 (en) 1999-03-16 2000-03-14 Apomorphine and sildenafil composition

Publications (1)

Publication Number Publication Date
BR0009016A true BR0009016A (pt) 2002-04-16

Family

ID=23029614

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009016-6A BR0009016A (pt) 1999-03-16 2000-03-14 Composição de apomorfina e sildenafil

Country Status (21)

Country Link
US (1) US6087362A (pt)
EP (1) EP1173178B1 (pt)
JP (1) JP2002539163A (pt)
CN (1) CN1350454A (pt)
AT (1) ATE302003T1 (pt)
AU (1) AU3744500A (pt)
BR (1) BR0009016A (pt)
CA (1) CA2367605A1 (pt)
CZ (1) CZ20013344A3 (pt)
DE (1) DE60022021T2 (pt)
DK (1) DK1173178T3 (pt)
ES (1) ES2244418T3 (pt)
HU (1) HUP0200549A3 (pt)
IL (1) IL145487A0 (pt)
MX (1) MXPA01009332A (pt)
NO (1) NO324511B1 (pt)
NZ (1) NZ514464A (pt)
PL (1) PL350313A1 (pt)
PT (1) PT1173178E (pt)
WO (1) WO2000054774A1 (pt)
ZA (1) ZA200107920B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP1315502B1 (en) * 2000-08-30 2010-03-17 Unimed Pharmaceuticals, LLC Method for treating erectile dysfunction and increasing libido in men
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
CA2435546A1 (en) * 2001-02-08 2002-08-15 Alice C. Martino Rapid-onset medicament for the treatment of sexual dysfunction
ES2180446B1 (es) * 2001-07-02 2004-01-16 Esteve Labor Dr Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AR036674A1 (es) * 2001-08-28 2004-09-29 Schering Corp Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicos
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US20030216407A1 (en) * 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
WO2003080074A1 (en) * 2002-03-19 2003-10-02 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7037257B1 (en) * 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
TWI330529B (en) * 2003-01-13 2010-09-21 Horphag Res Luxembourg Holding Sa A preparation for improving sperm quality or fertility,a kit comprising the same and uses thereof
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) * 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
PL1750766T3 (pl) * 2004-05-11 2013-12-31 Eb Ip Lybrido B V Preparaty farmaceutyczne i ich zastosowania do leczenia zaburzeń seksualnych u kobiet
CN106038572A (zh) * 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性***受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
CN101287470B (zh) 2005-10-12 2012-10-17 优尼麦德药物股份有限公司 改良的睾酮凝胶及使用方法
NZ579170A (en) * 2007-02-12 2012-05-25 Dmi Biosciences Inc Reducing side effects of tramadol
SG174079A1 (en) * 2007-02-12 2011-09-29 Dmi Biosciences Inc Treatment of comorbid premature ejaculation and erectile dysfunction
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
AR069979A1 (es) * 2007-12-26 2010-03-03 Biotest Ag Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
WO2009080832A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells
PL2242772T3 (pl) * 2007-12-26 2015-05-29 Biotest Ag Immunokonjugaty nakierowane na CD138 i ich zastosowanie
WO2009080829A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Agents targeting cd138 and uses thereof
US20090246298A1 (en) * 2008-03-31 2009-10-01 Ceola P. Steele Viagra
WO2010070617A1 (en) 2008-12-19 2010-06-24 Shimoda Biotech (Pty) Ltd Inclusion complexes of alpha-cyclodextrin and sildenafil salt
KR101725170B1 (ko) * 2009-05-06 2017-04-10 바이오테스트 아게 Ｃｄ１３８을 표적으로 하는 면역접합체의 용도
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
WO2010144817A1 (en) 2009-06-12 2010-12-16 Adagio Pharmaceuticals Ltd. Sublingual apomorphine
WO2012000634A1 (de) 2010-06-29 2012-01-05 Georg Bambach Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
HUE049349T2 (hu) 2010-12-16 2020-09-28 Sunovion Pharmaceuticals Inc Szublingvális filmek
WO2013083817A1 (en) 2011-12-08 2013-06-13 Biotest Ag Uses of immunoconjugates targeting cd138
CA3127926A1 (en) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
DK0758895T3 (da) * 1994-04-22 2000-06-13 Pentech Pharmaceuticals Inc Sublinguale dosisformer indeholdende apomorphin til anvendelse ved behandling af erektil dysfunktion
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
CA2291160C (en) * 1997-05-19 2008-10-28 Zonagen, Inc. Combination therapy for modulating the human sexual response
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction

Also Published As

Publication number Publication date
EP1173178A4 (en) 2002-09-04
DE60022021T2 (de) 2006-06-08
HUP0200549A2 (hu) 2002-07-29
CZ20013344A3 (cs) 2002-08-14
DE60022021D1 (de) 2005-09-22
NO20014519L (no) 2001-10-25
ATE302003T1 (de) 2005-09-15
JP2002539163A (ja) 2002-11-19
NZ514464A (en) 2004-01-30
US6087362A (en) 2000-07-11
PT1173178E (pt) 2005-11-30
EP1173178B1 (en) 2005-08-17
DK1173178T3 (da) 2005-11-07
WO2000054774A1 (en) 2000-09-21
ZA200107920B (en) 2003-03-26
PL350313A1 (en) 2002-12-02
HUP0200549A3 (en) 2004-07-28
NO324511B1 (no) 2007-11-05
CA2367605A1 (en) 2000-09-21
NO20014519D0 (no) 2001-09-17
MXPA01009332A (es) 2002-06-21
AU3744500A (en) 2000-10-04
CN1350454A (zh) 2002-05-22
ES2244418T3 (es) 2005-12-16
EP1173178A1 (en) 2002-01-23
IL145487A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
BR0009016A (pt) Composição de apomorfina e sildenafil
EA200300046A1 (ru) Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
JP2002522485A5 (pt)
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
BRPI0510862A (pt) medicamento para tratar disfunção sexual em um paciente, medicamento para tratar disfunção erétil em um paciente, medicamento para diminuir os efeitos colaterais associados com os agentes terapêuticos para tratar a disfunção sexual em um paciente, método para fabricação de um medicamento para tratamento da disfunção sexual de um paciente responsivo marginalmente ao inibidor de pde5, e uso do peptìdeo ac-nle-ciclo (-asp-his-d-phe-arg-trp-lys) -0h na perparação de um medicamento
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
AR012731A1 (es) Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible.
CO5251425A1 (es) Metodo y composiciones para administrar taxanos oralmente a pacientes humanos
NO20001828L (no) Metode for Õ forhindre nefrotoksisitet forÕrsaket av cyklosporiner og tacrolimus
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
YU61598A (sh) Tretmani bolesti uz korišćenje citokina
FI20011464A0 (fi) Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
BE1002256A3 (fr) Medicaments.
JP2001316293A5 (pt)
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
HUP9901935A2 (hu) Gyógyszerek és terápiás szerek és más glikozaminoglikánok (GAG) dózisainak célbajuttatására alkalmas dóziskészlet
MX2023008155A (es) Regimenes de tratamiento con dosis fijas de tamibaroteno.
James AZT twice-daily tablets approved: dosing concerns
BRPI0503488A (pt) agente de tratamento para sìndrome de intestino irritável com diarréia predominante
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
CS264081B1 (cs) Analgetický přípravek a anxiolytikem
RU99104174A (ru) Лечение психотических расстройств

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 10(VIII), 11, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.